The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. “Hospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,” AHA said in a letter to DEA. “These decreases would exacerbate these already dire shortages.” AHA said its request is “specific to these injectable medopications and does not extend to other dosage forms or opioid products.” Comments are due Sept. 19.

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Centers for Disease Control and Prevention this week announced an anticipated shortage of Aplisol, one of two TB skin tests licensed by the Food and Drug…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
A federal court in Texas yesterday ordered Pharm D Solutions to stop producing or distributing compounded drugs intended to be sterile until the company…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…